NLRP3 and infection: Although targeting the NLRP3 inflammasome has to date been shown to be effective in slowing disease progression and onset, there are currently no approved treatments which can ablate and/or downregulate its activity, a consequence of side effects and increased susceptibility to infection (Niu et al., 2019).